# US 2015/0105401 A1 · Mlk inhibitors and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105401 A1
- Document ID: US20150105401A1
- Status: Published application
- Kind: A1
- Application number: 14/508,566
- Filed: 2014-10-07
- Published: 2015-04-16
- Earliest claimed: 2008-11-25
- Assignees: University of Rochester
- Inventors: Harris A. Gelbard; Stephen Dewhurst; Val S. Goodfellow; Colin J. Loweth; Torsten Wiemann
- Web page: https://patentgrep.com/patent/US20150105401A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

## Claims

### Claim at position 1

1-71. (canceled)

### Claim 72

A compound having Formula (IX):
or a pharmaceutically acceptable salt thereof, wherein:
Y3 is chosen from a bond or CH2;
R3 is chosen from lower cycloalkyl and bicyclic heteroaryl, any of which are unsubstituted or substituted with one or more substituents chosen from halogen, hydroxy, lower amino, lower amido, lower phenylamido, lower phenylalkylamido, lower heterocycloalkyl, lower alkylheterocycloalkyl;
the moiety R14—Y4—R2 is chosen from
wherein
u is 0, 1, or 2;
wherein each R15 is independently chosen from halogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, lower amino, lower amido, lower sulfonamido, and lower sulfonyl,
Y4 is —CH2—; and
wherein R14 is chosen from lower cycloalkyl and lower heterocycloalkyl, any of which are unsubstituted or substituted with lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carboxy, lower alkylcarbonyl, lower carboxyester, lower carboxamido, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, sulfonate, or sulfonic acid.

### Claim 73 (depends on 72)

The compound as recited in claim 72, wherein Y3 is a bond.

### Claim 74 (depends on 72)

The compound as recited in claim 72, wherein R3 is chosen from benzothiazolyl, pyrrolopyridinyl, and indolyl, any of which is optionally substituted.

### Claim 75 (depends on 72)

The compound as recited in claim 72, wherein R3 is substituted with one or more substituents chosen from hydroxy, NH2, NH(CH3), N(CH3)2, C(O)NH2, C(O)NHCH3, morpholino, piperazinyl, methylpiperazinyl, acetamido, methylacetamido, methylpropionamido, phenylacetamidomethylene, benzamidomethylene, and phenylpropanamidomethylene.

### Claim 76 (depends on 72)

The compound as recited in claim 72, wherein Y3 is CH2 and R3 is optionally substituted lower cycloalkyl.

### Claim 77 (depends on 72)

The compound as recited in claim 72, wherein
u is 1 or 2; and
each R15 is independently chosen from fluorine, hydroxy, NH2, NH(CH3), N(CH3)2, NHS(O)2CH3, methoxy, and methyl.

### Claim 78 (depends on 72)

The compound as recited in claim 72, wherein u is 0.

### Claim 79 (depends on 72)

The compound as recited in claim 72, wherein
R3 is optionally substituted 5/6-fused bicyclic heteroaryl; and
R14 is substituted or unsubstituted monocyclic heterocycloalkyl.

### Claim 80 (depends on 72)

The compound as recited in claim 72, wherein R14 is substituted or unsubstituted lower heterocycloalkyl.

### Claim 81 (depends on 72)

The compound as recited in claim 72, wherein R14 is substituted or unsubstituted piperazinyl.

### Claim 82 (depends on 72)

A pharmaceutical composition comprising a compound as recited in claim 72 together with a pharmaceutically acceptable carrier.

### Claim 83 (depends on 72)

A method of inhibiting mixed lineage kinase-3 activity in a patient, comprising the step of administering to said patient a therapeutically effective amount of a compound as recited in claim 72.

### Claim 84 (depends on 83)

The method as recited in claim 83, wherein the patient has depression, bipolar disorder, or post-traumatic stress disorder.

### Claim 85 (depends on 83)

The method as recited in claim 83, wherein the patient has traumatic brain injury.

### Claim 86 (depends on 83)

The method as recited in claim 83, wherein the patient has Alzheimer's Disease, Parkinson's Disease, or human immunodeficiency virus associated neurocognitive disorder.

### Claim 87 (depends on 83)

The method as recited in claim 83 wherein the patient has a neurologic disorder of hearing or vision.

### Claim 88 (depends on 83)

The method as recited in claim 83, wherein said disorder is chosen from ototoxicity, hearing loss, acute injury to the inner ear, acoustic trauma, and injury resulting from blast noise.
